Recombinant protein vaccine (NDV-3) against S.aureus and Candida (NovaDigm Therapeutics)

N/A

Report date: 2024/10/15 20:00:08

Base Information

Drug NameRecombinant protein vaccine (NDV-3) against S.aureus and Candida (NovaDigm Therapeutics)
Drug Alias NameProphylactic candidiasis/MRSA vaccineLead Candida-Staph vaccineNDV-3NDV-3A
ClassificationVaccines > Application > Prophylactic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsJob SyndromeCandidiasis, VulvovaginalCandidiasis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesLa BiomedNovadigm
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovadigm Therapeutics IncNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsN/A
Inactive IndicationsJob SyndromeCandidiasis, VulvovaginalCandidiasis +[4] 

Other Information

ATC CodeN/A
Related LinksN/A